Overview

Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2018-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of apatinib mesylate combined with pemetrexed alone in advanced non-small cell lung cancer patients in the second or second line of treatment of progression-free survival

Phase:

Phase 2

Details

Lead Sponsor:

Wuling Ou

Collaborators:

Hubei Clinical Research Collaboration Group
Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Apatinib
Pemetrexed